Table 4.
Proportion of patients reporting hypoglycemia.
| Comparators | References | DPP-4I (#events/N) | Comparator (#events/N) | Risk ratio (95% CI) | I2Q-test |
|---|---|---|---|---|---|
| Any hypoglycemia | |||||
| MRI: placebo (W24–52) | 24, 27, 28, 30 | 78/298 | 61/224 | 1.04 (0.74–1.45) | 20%, P = 0.29 |
| SRI: placebo (W52) | 28, 30 | 23/112 | 15/87 | 1.24 (0.69–2.23) | 0% |
| Dialysis: placebo (W52) | 28 | 4/19 | 5/20 | 0.84 (0.27–2.67) | NA |
| Dialysis: glipizide (W54) | 18 | 4/64 | 7/65 | 0.58 (0.18–1.89) | NA |
| Severe hypoglycemia | |||||
| Placebo: W12–24 | 24, 31 | 6/356 | 4/251 | 0.92 (0.26–3.19) | 0% |
| Placebo: W52–54 | 26–28, 30 | 8/428 | 12/371 | 0.62 (0.25–1.55) | 0% |
| Glipizide/glimepiride: W52–54 | 19, 20, 25 | 9/388 | 14/360 | 0.6 (0.21–1.74) | 29%, P = 0.25 |
| Vildagliptin: W24 | 21 | 2/65 | 1/83 | 2.55 (0.24–27.55) | NA |
DPP-4I: dipeptidyl peptidase-4 inhibitors; #events/N: number of events per sample; CI: confidence interval; NA: not applicable; MRI: moderate renal impairment (estimated clearance = 30–50 mL/min); SRI: severe renal impairment (estimated clearance < 30 mL/min); W: weeks.